Pharvaris (NASDAQ:PHVS) Hits New 1-Year High – Here’s Why

Pharvaris N.V. (NASDAQ:PHVS) shares reached a new 52-week high on Wednesday . The company traded as high as $33.50 and last traded at $33.3850, with a volume of 81367 shares traded. The stock had previously closed at $31.46.

Analyst Upgrades and Downgrades

PHVS has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Pharvaris in a report on Tuesday. Citizens Jmp lowered their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. UBS Group set a $74.00 target price on shares of Pharvaris in a report on Wednesday, May 13th. Citigroup restated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Wolfe Research initiated coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price on the stock. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Trading Up 5.5%

The stock’s 50-day moving average price is $29.71 and its two-hundred day moving average price is $27.63. The stock has a market capitalization of $2.17 billion, a P/E ratio of -10.40 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, equities research analysts predict that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Insider Activity

In other news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the transaction, the director directly owned 355,167 shares of the company’s stock, valued at $10,768,663.44. This represents a 7.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anne Lesage sold 21,700 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total transaction of $656,642.00. Following the transaction, the insider directly owned 56,450 shares of the company’s stock, valued at $1,708,177. This represents a 27.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 212,618 shares of company stock worth $6,350,564.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris during the 4th quarter valued at $35,000. JPMorgan Chase & Co. raised its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Pharvaris during the 3rd quarter valued at $75,000. Barclays PLC purchased a new stake in shares of Pharvaris during the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris during the 4th quarter valued at $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.